News Center

January 12, 2026

Variantyx Expands into Germline Hematologic Cancer Testing with Two New Tests

We have expanded our clinical testing portfolio with the launch of two new germline assays designed to address the unique...
August 20, 2025

Introducing a Curated Cardiomyopathies and Arrhythmia Panel with Unparalleled Specificity, Sensitivity and Clinical Utility

Hereditary cardiomyopathies and arrhythmias are major contributors to morbidity and mortality worldwide. Cardiomyopathy refers to primary disorders of the cardiac...
October 15, 2024

Variantyx Combines Long and Short Reads for Rare Disease Whole-Genome Diagnostic Test

GenomeWeb recently wrote a profile on Genomic Unity 2.0® – the first commercially available test to incorporate third-generation long-read Oxford...
July 5, 2023

Variantyx updates secondary findings reporting policy to ACMG v3.2

Just 13 days ago, June 22nd to be exact, the American College of Medical Genetics and Genomics (ACMG) published the...
April 5, 2023

Variantyx welcomes two new Novaseq XPlus sequencers

Today we officially welcomed two new Illumina Novaseq XPlus sequencers with a company-wide ribbon cutting ceremony. We can’t wait to complete validation (already under way!)…
August 31, 2021

ACMG secondary findings updated list for reporting of secondary findings, for medically actionable genes in clinical exome and genome sequencing

ACMG secondary findings updated list for reporting of secondary findings, for medically actionable genes in clinical exome and genome sequencing. ...
May 11, 2021

Variantyx Expands Into Prenatal, Cancer Testing

Genomeweb | May 11, 2021 Variantyx, a genetic testing company offering clinical whole-genome sequencing-based assays, is expanding its menu to...
January 12, 2021

Variantyx Surpasses 2,500 Genomes Analyzed, Highlights the Value of Its WGS-Based Testing Methodology

January 12, 2021 Clinicians at Variantyx, a leader in high complexity hereditary disease testing, recently completed analysis of their 2,500th...